A plain-English tracker of what's actually legal in peptide therapy right now, and where to get it properly.

Updated — Nov 15, 2026
Regulatory status · Updated as it changes

HHS won't penalize pharmacies for compounding six peptides. None is FDA-approved.

On July 23–24, 2026, an FDA advisory committee recommended BPC-157, KPV, TB-500, MOTS-c, Epitalon, and Semax for the federal compounding list, over the objection of FDA staff. The vote is nonbinding, none of them is FDA-approved or on that list yet, and the FDA hasn't proposed a rule.

Latest · Nov 13, 2026The public comment period on HHS's interim peptide policy closed. The policy still isn't an approval or a listing on the FDA's compounding list, and HHS can change it. One pharmacy has announced plans to start with BPC-157 by December. What the policy does and doesn't do →

Primary sources first  ·  FDA status tracked  ·  Not a pharmacy

We're not a clinical or legal practice ourselves. Our background is behavioral health technology and operations. This tracker follows FDA public actions directly. Confirm specifics with a licensed provider. How we check facts →

Pick your question

Each of these has its own page with the full answer, the timeline, and the sources.

Are peptides legal in the US in 2026? Quick answers

The short version, in case that's all you need.

Q

What does HHS's October 28 peptide policy actually allow?

It's an enforcement-discretion policy, not a change in the law and not an FDA approval. HHS says it generally won't take action against state-licensed pharmacies, federal facilities, or licensed physicians that compound BPC-157, KPV, TB-500, MOTS-c, Epitalon, or Semax, as long as conditions are met. They include a valid patient-specific prescription, single-ingredient products with no blends, bulk ingredient from an FDA-registered manufacturer with a certificate of analysis, adverse-event reporting, and limits on the forms each peptide can take. HHS says it can revisit the policy, and state rules still apply. It covers pharmacy compounding, not products sold as research use only.

Full answer →
Q

Is BPC-157 legal in the US right now?

Not formally, but the picture just shifted. BPC-157 isn't FDA-approved and isn't on the list that authorizes pharmacies to compound it. Since Oct 28, HHS says it generally won't take enforcement action against pharmacies and physicians that compound it under set conditions, including a patient-specific prescription. One pharmacy has announced plans to offer it by December. FDA reviewers said the human safety data is limited. Ask any provider exactly what they're dispensing, which pharmacy fills it, and where the ingredient comes from.

Full answer →
Q

What did the FDA's July 2026 vote actually decide?

Nothing final on its own. The committee advised the FDA to add six of the seven peptides it reviewed to the compounding list, several by narrow margins. FDA staff had recommended against all seven. The FDA still has to propose a rule, take public comment, and issue a final rule. In October, HHS issued an interim policy covering the same six peptides while that process plays out.

Full answer →
Q

Is compounded semaglutide or tirzepatide still legal?

Only in narrow cases. The shortages that allowed broad compounding ended in 2024 and 2025. A pharmacy can still compound for an individual patient when a prescriber documents a medical need the approved drug can't meet. Lower cost doesn't count under FDA policy.

Full answer →
Q

Can I get retatrutide legally right now?

No. Retatrutide isn't FDA-approved and can't be legally compounded, so a clinical trial is the only legitimate access. Eli Lilly plans to apply for FDA approval in the first quarter of 2027, so approval, if it comes, isn't expected before late 2027.

Full answer →
Q

Does a lab report (COA) make a research-use-only peptide legal?

No. A certificate of analysis is a document the seller provides. It isn't FDA clearance and it doesn't make a product legal for human use. In August 2026 the FDA sent warning letters to five peptide sellers, saying products marketed as research use only were unapproved drugs intended for human use. HHS's October policy covers pharmacy compounding under a prescription, not these sellers.

Full answer →
Q

Does 'no longer restricted' or 'allowed to compound' mean a peptide is safe?

No. In April 2026 the FDA took twelve peptides off its highest-risk list, and in October HHS said it won't penalize pharmacies for compounding six peptides. Neither is an approval or a safety finding. FDA reviewers said human safety data on these peptides is limited, and compounded drugs aren't reviewed by the FDA for safety or quality, which can vary between pharmacies.

Three ways people get these, and where the law stands in each

Where you get a peptide decides what's legal. The same compound can be clearly legal, unsettled, or off limits depending on the route.

1. Retail pharmacy, with a prescription

Clearly legal

A doctor prescribes an FDA-approved drug and a regular pharmacy fills it, the way CVS or Walgreens would. This is the route for semaglutide, tirzepatide, and other approved GLP-1s, sometimes with insurance.

None of the six peptides on this tracker are FDA-approved, so this route isn't available for them.

2. Provider plus a compounding pharmacy

Unsettled

A clinic or telehealth provider evaluates you and prescribes, and a state-licensed compounding pharmacy prepares the medication and mails it to you.

For the six peptides, this route changed on Oct 28. They still aren't FDA-approved or on the FDA's compounding list, but HHS now says it generally won't take enforcement action against pharmacies and physicians that compound them under set conditions, including a patient-specific prescription. It's an interim policy that HHS can revisit, and state rules still apply.

For compounded semaglutide and tirzepatide, FDA policy allows compounding only when a clinician documents a patient-specific need, not to save money, and the agency is enforcing that. The GLP-1 rules in full →

This is where quality varies most. How to vet a provider →

3. “Research use only” suppliers

Not a legal route

Sold as lab chemicals with no prescriber and no pharmacy. A certificate of analysis (COA) is a report the seller provides. It isn't FDA clearance, and it doesn't make a product legal for human use.

In letters dated August 24, the FDA told five online peptide sellers that products marketed this way were unapproved new drugs intended for human use. HHS's October policy doesn't change that: it covers pharmacy compounding, not these sellers. Purity, dose, and sterility are unverified. This site doesn't rank, review, or link to sellers in this channel. Why the label doesn't make it legal →

The differences at a glance

How the three routes differ. A “compounded” drug is made by a pharmacy for an individual patient and isn't reviewed by the FDA the way an approved drug is.
What differs1. Retail pharmacy2. Provider + compounding pharmacy3. Research use only
Where you'll see itYour doctor, then a retail pharmacy such as CVS or WalgreensTelehealth, wellness, and anti-aging clinics, with a partner compounding pharmacy that mails it to youOnline stores selling peptides as lab chemicals
Who prescribesA licensed clinicianA licensed clinician, often after an online intakeNo one
Who makes itA drug manufacturer working to FDA standardsA state-licensed compounding pharmacy, or an FDA-registered outsourcing facilityAn unregulated supplier
FDA review of safety and effectivenessYes, before approvalNo. Compounded drugs aren't FDA-approvedNo
Quality checksFDA-regulated manufacturing and inspectionsVaries by pharmacy. State pharmacy boards oversee themOnly a seller-supplied lab report (COA), which isn't a regulator's finding
Legal status todayClearly legal
With a prescription
Unsettled
Interim HHS relief for six peptides
Not a legal route
To human use

How to choose a provider

The quality gap between telehealth companies is wide. Check these before you sign up with anyone.

Where each peptide stands

Six were recommended and one wasn't. What each one is and what it's studied for →

BPCKPVTB-500MOTS-cEPISEMAXDSIP

Recommended by the committee (6)   Not recommended (1)

Status as of the update date above. “HHS interim policy” means HHS says it generally won't take enforcement action against compounding it under set conditions. It isn't an FDA approval or a listing.
CompoundJuly voteStatus
BPC-157Recommended 8–6HHS interim policy
KPVRecommended 8–6HHS interim policy
TB-500Recommended 8–6HHS interim policy
MOTS-cRecommended 7–5HHS interim policy
EpitalonRecommendedHHS interim policy
SemaxRecommendedHHS interim policy
Emideltide (DSIP)Not recommended 7–6Not recommended
Not covered by the HHS policy

The docket

Every step that got us here, in order. We update this whenever something changes.

  1. Sept 2023
    Category 2 listingFDA places BPC-157 and TB-500 on its restricted list, barring US compounding pharmacies from producing them.
  2. 2024–2025
    Enforcement widensWarning letters and account shutdowns hit noncompliant compounders and unlicensed sellers across the category.
  3. Feb 27, 2026
    HHS signals a reversalFederal health officials publicly acknowledge the restrictions had been pushing patients toward the unregulated gray market.
  4. Apr 2026
    Twelve peptides leave Category 2FDA lifts the “significant safety risk” flag. That's a door opening, not a legalization. With one exception (GHK-Cu), they weren't moved to the interim tier where FDA tolerates compounding.
  5. Jun 29, 2026
    Committee reconstitutedThe advisory committee had only 3 standing voting members against an authorized 12. FDA announces at least 8 new members, some with ties to peptide businesses or clinics, ahead of the July vote.
  6. Jul 23–24, 2026
    Advisory committee votesSix of seven peptides recommended, several narrowly. Emideltide (DSIP) was rejected 7–6. FDA staff had recommended against all seven. Full breakdown →
  7. Aug 24, 2026
    Warning letters to five sellersFDA's drug center warns Peptide Partners, Peak Performance Peptides, Royal Peptides, NuScience Peptides, and Tex Peptides. The letters say products sold under research-use labels were unapproved drugs intended for human use. Posted publicly Sep 1.
  8. Oct 15, 2026
    Interim access policy goes to the White HouseHHS and the FDA submit a draft policy for compounding certain peptides for White House review. The text wasn't public at the time. What came next →
  9. Oct 28, 2026
    HHS issues an interim enforcement-discretion policyHHS says it generally won't take enforcement action against state-licensed pharmacies, federal facilities, or licensed physicians compounding BPC-157, KPV, TB-500, MOTS-c, Epitalon, or Semax under set conditions. It isn't an approval, and it stays in place for each peptide until the FDA addresses it in a final rule. FDA reviewers had recommended against all of them. What it does and doesn't do →
  10. Oct 30, 2026
    Notice in the Federal RegisterThe policy appears in the Federal Register (doc. 2026-22192, docket HHS-OASH-2026-0496) with a two-week public comment period, which closed on November 13.
  11. Nov 12, 2026
    A pharmacy announces plans under the policyA company that runs both a 503A pharmacy and a 503B facility says its 503A pharmacy will start with BPC-157 for patients with a valid prescription and aims to have covered peptides available by December. KPV, TB-500, MOTS-c, Semax, and Epitalon would be evaluated after that, with no timing given. A company announcement, not a regulatory finding.
  12. Nov 13, 2026
    Comment period closesPublic comments on the HHS policy were due two weeks after the Federal Register notice. The policy remains in place until the FDA addresses each peptide in a final rule.
  13. Pending
    A formal FDA determinationThe HHS policy is interim, and the committee's vote is nonbinding. Formal listing still needs a proposed rule, a comment period, and a final rule. A second committee meeting on five more peptides is due before the end of February 2027.

GLP-1s: semaglutide, tirzepatide, and retatrutide

The most-searched corner of the category, and the one where the rules have moved the most in the last two years.

GLP-1 legal status as of the update date above.
DrugWhere it standsStatus
Semaglutide and tirzepatide
Wegovy, Ozempic, Zepbound, Mounjaro
FDA-approved. Prescribable today through a licensed provider and filled at pharmacies.Approved
Compounded semaglutide and tirzepatideLimited to a documented patient-specific need since the shortages ended. FDA is enforcing against mass-marketed copies.Narrow exception
RetatrutideInvestigational. Can't be compounded under federal law. Clinical trials are the only legitimate access.No legal route

What changed for compounded GLP-1s, and what to ask your provider →

Sources

Primary sources first. Where we cite law-firm, trade, or press coverage, it's linked so you can read it yourself. Each topic page lists its own sources.

Get an email when the FDA rules.

One short email when the FDA proposes or finalizes anything on peptide compounding, or when the GLP-1 rules change. Nothing else.

Free. Every email includes an unsubscribe link, and we don't sell or share your address.